| Index | S&P 500 | P/E | 13.54 | EPS (ttm) | 4.54 | Insider Own | 0.09% | Shs Outstand | 2.04B | Perf Week | 2.90% |
| Market Cap | 125.59B | Forward P/E | 9.29 | EPS next Y | 6.62 | Insider Trans | -0.37% | Shs Float | 2.04B | Perf Month | -0.03% |
| Enterprise Value | 157.64B | PEG | - | EPS next Q | - | Inst Own | 73.78% | Short Float | 2.25% | Perf Quarter | -1.73% |
| Income | 9.28B | P/S | 2.55 | EPS this Y | 3.63% | Inst Trans | 0.00% | Short Ratio | 4.16 | Perf Half Y | 4.72% |
| Sales | 49.19B | P/B | 5.63 | EPS next Y | 4.40% | ROA | 10.59% | Short Interest | 45.85M | Perf YTD | 13.98% |
| Book/sh | 10.93 | P/C | 11.35 | EPS next 5Y | -6.31% | ROE | 46.75% | 52W High | 68.64 -10.43% | Perf Year | 38.50% |
| Cash/sh | 5.42 | P/FCF | 10.98 | EPS past 3/5Y | 5.36% - | ROIC | 15.40% | 52W Low | 42.52 44.59% | Perf 3Y | 8.14% |
| Dividend Est. | 2.52 (4.10%) | EV/EBITDA | 9.37 | Sales past 3/5Y | 1.45% 2.54% | Gross Margin | 70.16% | Volatility | 2.84% 2.87% | Perf 5Y | 5.35% |
| Dividend TTM | 2.52 (4.10%) | EV/Sales | 3.20 | EPS Y/Y TTM | 202.95% | Oper. Margin | 28.14% | ATR (14) | 1.84 | Perf 10Y | 22.37% |
| Dividend Ex-Date | Oct 02, 2026 | Quick Ratio | 1.39 | Sales Y/Y TTM | 1.84% | Profit Margin | 18.87% | RSI (14) | 51.05 | Recom | 2.60 |
| Dividend Gr. 3/5Y | 4.71% 1.61% | Current Ratio | 1.53 | EPS Q/Q | 39.73% | SMA20 | 1.75% | Beta | 0.20 | Target Price | 66.08 |
| Payout | 54.89% | Debt/Eq | 2.54 | Sales Q/Q | 5.74% | SMA50 | -2.72% | Rel Volume | 0.82 | Prev Close | 63.00 |
| Employees | 32,500 | LT Debt/Eq | 2.41 | Earnings | Oct 29 | SMA200 | 2.79% | Avg Volume | 11.81M | Price | 61.48 |
| IPO Date | Jun 01, 1972 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 27.73% 10.51% | Net Debt/EBITDA | 2.05 | Volume | 9,729,786 | Change | -2.41% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-12-26 | Reiterated | Jefferies | Buy | $73 → $76 |
| Oct-08-26 | Reiterated | Cantor Fitzgerald | Neutral | $59 → $53 |
| Oct-07-26 | Reiterated | Morgan Stanley | Underweight | $40 → $41 |
| Oct-05-26 | Downgrade | Leerink Partners | Outperform → Market Perform | $60 → $59 |
| Sep-23-26 | Reiterated | Goldman Sachs | Neutral | $57 → $63 |
| Sep-16-26 | Reiterated | Piper Sandler | Overweight | $75 → $82 |
| Sep-10-26 | Reiterated | HSBC | Hold | $53 → $65 |
| Aug-05-26 | Reiterated | Roth Capital | $75 | |
| Aug-05-26 | Upgrade | Argus Research | Hold → Buy | $75 |
| Jul-31-26 | Reiterated | Guggenheim | Buy | $72 → $75 |
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 49,187 | 48,195 | 48,300 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 14,679 | 13,936 | 13,968 | — | — | — | — | — | — | |
| Gross Profit | 34,508 | 34,259 | 34,332 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 7,413 | 7,267 | 8,414 | — | — | — | — | — | — | |
| Research and Development | 10,722 | 9,951 | 11,159 | — | — | — | — | — | — | |
| Other Operating Expense | 2,531 | 3,317 | 8,872 | — | — | — | — | — | — | |
| Operating Income | 13,842 | 13,724 | 5,887 | — | — | — | — | — | — | |
| Interest Expense | 1,730 | 1,891 | 1,947 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -202 | -2,505 | -12,319 | — | — | — | — | — | — | |
| Net Income Before Taxes | 11,910 | 9,328 | -8,379 | — | — | — | — | — | — | |
| Income Taxes | 2,634 | 2,272 | 554 | — | — | — | — | — | — | |
| Consolidated Net Income | 9,282 | 7,054 | -8,948 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 9,275 | 7,056 | -8,933 | — | — | — | — | — | — | |
| Net Income | 9,282 | 7,054 | -8,948 | — | — | — | — | — | — | |
| EPS (Recurring) | 4.54 | 3.46 | -4.41 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 4.54 | 3.46 | -4.41 | — | — | — | — | — | — | |
| EPS (Diluted) | 4.54 | 3.45 | -4.41 | — | — | — | — | — | — | |
| EBITDA | 16,816 | 15,230 | 3,168 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 13.54 | 15.63 | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 2.55 | 2.28 | 2.37 | — | — | — | — | — | — | |
| Gross Margin | 70.16 | 71.08 | 71.08 | — | — | — | — | — | — | |
| Operating Margin | 28.14 | 28.48 | 12.19 | — | — | — | — | — | — | |
| Net Margin | 18.87 | 14.64 | -18.53 | — | — | — | — | — | — | |
| Shares Outstanding | 2,042 | 2,041 | 2,027 | — | — | — | — | — | — | |
| Market Capitalization | 125,542 | 110,092 | 114,647 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Gallman Cari | EVP, General Counsel | Oct 02 '26 | Option Exercise | 0.00 | 4,559 | 0 | 18,208 | Oct 05 |
| Massacesi Cristian | EVP,Chief Med Offr,Head of Dev | Sep 09 '26 | Sale | 64.57 | 6,249 | 403,498 | 18,748 | Sep 10 |
| Short Bartie Wendy | EVP, Corporate Affairs | Sep 01 '26 | Option Exercise | 66.92 | 1,236 | 82,713 | 13,317 | Sep 03 |
| Holzer Phil M | SVP and Controller | Aug 25 '26 | Sale | 67.50 | 500 | 33,750 | 16,862 | Aug 26 |
| Massacesi Cristian | EVP,Chief Med Offr,Head of Dev | Aug 01 '26 | Option Exercise | 0.00 | 51,172 | 0 | 51,172 | Aug 04 |
| Gallman Cari | EVP, General Counsel | Aug 01 '26 | Option Exercise | 0.00 | 1,061 | 0 | 14,192 | Aug 04 |
| Haller Julia A | Director | Jun 15 '26 | Option Exercise | 53.76 | 20,460 | 1,099,930 | 34,079 | Jun 16 |
| Short Bartie Wendy | EVP, Corporate Affairs | Jun 03 '26 | Option Exercise | 0.00 | 8,040 | 0 | 15,957 | Jun 05 |
| Lenkowsky Adam | EVP, Chief Commercial Officer | May 01 '26 | Option Exercise | 0.00 | 1,373 | 0 | 20,508 | May 05 |
| Shanahan Karin | EVP, Chief Supply Chain & Ops | Apr 01 '26 | Option Exercise | 0.00 | 3,307 | 0 | 27,580 | Apr 02 |
| Elkins David V | EVP, Chief Financial Officer | Apr 01 '26 | Sale | 61.67 | 30,000 | 1,850,016 | 159,248 | Apr 02 |
| Short Bartie Wendy | EVP, Corporate Affairs | Mar 10 '26 | Option Exercise | 0.00 | 5,883 | 0 | 10,952 | Mar 12 |
| Shanahan Karin | EVP, Chief Supply Chain & Ops | Mar 10 '26 | Option Exercise | 0.00 | 25,501 | 0 | 39,120 | Mar 12 |
| Plenge Robert M | EVP, Chief Research Officer | Mar 10 '26 | Option Exercise | 0.00 | 17,501 | 0 | 31,600 | Mar 12 |
| Meyers Gregory Scott | EVP, Chief Digital & Tech Off. | Mar 10 '26 | Option Exercise | 0.00 | 25,892 | 0 | 44,330 | Mar 12 |